# Comprehensive FDA Catalyst Events: September 2025 — February 2026

**Compiled:** 2026-02-14
**Purpose:** Complete universe for ODIN v10.68 historical accuracy audit
**Sources:** FDA.gov, BioPharmCatalyst, FiercePharma, company press releases, PubMed

---

## MASTER EVENT LIST

### APPROVALS (Positive Outcomes)

| # | Ticker | Company | Drug (Brand) | Indication | TA | PDUFA Date | Actual Date | Type | Key Details |
|---|--------|---------|-------------|-----------|-----|-----------|-------------|------|-------------|
| 1 | LLY | Eli Lilly | Imlunestrant (Inluriyo) | ER+/HER2- breast cancer | Oncology | Oct 2025 | Oct 2, 2025 | NDA | SERD, ESR1-mutated |
| 2 | BI (private) | Boehringer Ingelheim | Nerandomilast (Jascayd) | IPF | Pulmonology | Oct 7, 2025 | Oct 2025 | NDA | First new IPF drug in 10 years, PDE4B inhibitor |
| 3 | JAZZ/RHHBY | Jazz/Roche | Lurbinectedin + Atezolizumab | ES-SCLC maintenance | Oncology | Oct 7, 2025 | Oct 2, 2025 | sNDA | Priority Review, IMforte Phase 3 |
| 4 | AZN/AMGN | AstraZeneca/Amgen | Tezepelumab (Tezspire) | CRSwNP (nasal polyps) | Immunology | Oct 2025 | Oct 17, 2025 | sBLA | WAYPOINT Phase 3, second indication |
| 5 | GSK | GSK | Belantamab mafodotin (Blenrep) | R/R Multiple Myeloma | Oncology | Oct 24, 2025 | Oct 24, 2025 | sBLA | ADC, with bortezomib+dex |
| 6 | SNDX | Syndax Pharma | Revumenib (Revuforj) | R/R NPM1-mutated AML | Oncology | Nov 2025 | Nov 6, 2025 | sNDA | Menin inhibitor, Priority Review |
| 7 | KURA | Kura Oncology | Ziftomenib (Komzifti) | R/R NPM1-mutated AML | Oncology | Nov 30, 2025 | Nov 13, 2025 | NDA | Menin inhibitor, approved early |
| 8 | ARWR | Arrowhead Pharma | Plozasiran (Redemplo) | FCS triglycerides | Cardio/Rare | Nov 18, 2025 | Nov 18, 2025 | BLA | First siRNA for FCS, PALISADE study |
| 9 | JNJ | Johnson & Johnson | Daratumumab (Darzalex Faspro) | Light chain amyloidosis | Oncology | Nov 2025 | Nov 19, 2025 | sBLA | Traditional approval, with VCd |
| 10 | INVA | Innoviva | Zoliflodacin (Nuzolvence) | Gonorrhea | Infectious Disease | Dec 2025 | Dec 2025 | NDA | First new oral gonorrhea tx |
| 11 | MIST | Milestone Pharma | Etripamil (Cardamyst) | PSVT | Cardiology | Dec 2025 | Dec 12, 2025 | NDA | Post-CRL resubmission (CRL Mar 2025 for CMC/nitrosamines) |
| 12 | DAIICHI/AZN | Daiichi Sankyo/AZ | Enhertu + Pertuzumab | 1L HER2+ breast cancer | Oncology | Jan 23, 2026 | Dec 15, 2025 | sBLA | Approved early, DESTINY-Breast09 |
| 13 | GSK | GSK | Depemokimab (Exdensur) | Severe eosinophilic asthma | Pulmonology | Dec 2025 | Dec 17, 2025 | BLA | Anti-IL-5 biologic |
| 14 | CYTK | Cytokinetics | Aficamten (Myqorzo) | Obstructive HCM | Cardiology | Dec 26, 2025 | Dec 19, 2025 | NDA | Cardiac myosin inhibitor |
| 15 | AMRX | Amneal Pharma | Denosumab-mobz (Boncresa) | Biosimilar (Prolia/Xgeva) | Biosimilar | Dec 2025 | Dec 22, 2025 | BLA | Interchangeable biosimilar |
| 16 | NVO | Novo Nordisk | Oral Semaglutide (Wegovy pill) | Obesity/weight management | Metabolic | Dec 2025 | Dec 22, 2025 | sNDA | First oral GLP-1 for obesity |
| 17 | AGIO | Agios Pharma | Mitapivat (Aqvesme) | Thalassemia anemia | Hematology/Rare | Dec 2025 | Dec 23, 2025 | sNDA | Pyruvate kinase activator |
| 18 | OMER | Omeros Corp | Narsoplimab (Yartemlea) | TA-TMA | Hematology/Rare | Sep 2025→Dec 2025 | Dec 23, 2025 | BLA | Post-CRL resubmission, MASP-2 inhibitor |
| 19 | VNDA | Vanda Pharma | Tradipitant (Nereus) | Motion sickness | Neurology | Dec 30, 2025 | Dec 30, 2025 | NDA | NK-1 antagonist, first in 40 years |
| 20 | ARQT | Arcutis Biotherapeutics | Roflumilast (Zoryve) foam | Plaque psoriasis | Dermatology | May 2025 | May 22, 2025 | sNDA | Foam formulation |
| 21 | ARQT | Arcutis Biotherapeutics | Roflumilast (Zoryve) cream | AD in children 2-5 | Dermatology | Oct 13, 2025 | Oct 6, 2025 | sNDA | Age expansion |
| 22 | FBIO/SNYN | Fortress/Sentynl | Copper histidinate (Zycubo) | Menkes disease | Rare/Genetic | Jan 14, 2026 | Jan 12, 2026 | NDA | Post-CRL resubmission (CRL Oct 2025 CMC) |
| 23 | MRK | Merck | Keytruda + Paclitaxel | PD-L1+ ovarian cancer | Oncology | Feb 2026 | Feb 11, 2026 | sBLA | Platinum-resistant |

### CRLs / REJECTIONS (Negative Outcomes)

| # | Ticker | Company | Drug | Indication | TA | PDUFA Date | CRL Date | Reason |
|---|--------|---------|------|-----------|-----|-----------|----------|--------|
| 24 | SRRK | Scholar Rock | Apitegromab | SMA | Neurology/Rare | Sep 2025 | Sep 2025 | CMC: fill-finish facility (Catalent) |
| 25 | SNY | Sanofi | Tolebrutinib | nrSPMS | Neurology | Sep 28→Dec 28, 2025 | Dec 24, 2025 | DILI risk (6 Hy's Law cases), unclear benefit |
| 26 | CAPR | Capricor Therapeutics | Deramiocel (CAP-1002) | DMD cardiomyopathy | Rare/CBER | Aug 31, 2025 | Jul 11, 2025 | Insufficient efficacy evidence |
| 27 | BHVN | Biohaven | Troriluzole (Vyglxia) | SCA | Neurology/Rare | Nov 4, 2025 | Nov 4, 2025 | External control inadequacy |
| 28 | RGNX | Regenxbio | RGX-121 | MPS II (Hunter) | Rare/CBER | Feb 8, 2026 | Feb 7, 2026 | Population def, surrogate concerns, clinical hold |
| 29 | IRON | Disc Medicine | Bitopertin | EPP | Hematology/Rare | Feb 13, 2026 | Feb 13, 2026 | [Post-mortem completed] |
| 30 | AQST | Aquestive | Anaphylm (epinephrine film) | Anaphylaxis | Allergy | Jan 31, 2026 | Jan 30, 2026 | Human factors, labeling, PK study |
| 31 | ATRA | Atara Bio | Tabelecleucel (Ebvallo) | EBV+ PTLD | Oncology/CBER | Jan 10, 2026 | Jan 9, 2026 | 2nd CRL: single-arm study inadequate |

### DELAYS / EXTENSIONS (Still Pending)

| # | Ticker | Company | Drug | Indication | Original PDUFA | New PDUFA | Status |
|---|--------|---------|------|-----------|----------------|-----------|--------|
| 32 | ASND | Ascendis Pharma | TransCon CNP (navepegritide) | Achondroplasia | Nov 2025 | Feb 28, 2026 | Extended 3 months (major amendment) |
| 33 | TVTX | Travere Therapeutics | Sparsentan (Filspari) | FSGS | Jan 13, 2026 | Apr 13, 2026 | Extended 3 months |
| 34 | ALDX | Aldeyra Therapeutics | Reproxalap | Dry Eye Disease | Dec 16, 2025 | Mar 16, 2026 | Extended 3 months (3rd NDA attempt) |

### DATA READOUTS (Non-PDUFA Binary Events)

| # | Ticker | Company | Drug | Event | Date | Outcome | Stock Move |
|---|--------|---------|------|-------|------|---------|-----------|
| 35 | CAPR | Capricor Therapeutics | Deramiocel (CAP-1002) | HOPE-3 Phase 3 data | Dec 3, 2025 | POSITIVE (+54% skeletal, +91% cardiac) | +404% |
| 36 | TOVX | Theriva Biologics | VCN-01 | Phase 2b data readout | ~Nov 2025 | POSITIVE | +92% |

---

## SUMMARY STATISTICS

| Category | Count |
|----------|-------|
| Approvals | 23 |
| CRLs/Rejections | 8 |
| Delays/Extensions | 3 |
| Data Readouts | 2 |
| **Total Events** | **36** |

### Approval Rate: 23 / 31 PDUFA decisions = **74.2%**
(excludes data readouts and pending delays)

---

## EVENTS IN ODIN'S CURRENT DATABASE (App.jsx)

The following events from this list are currently scored in ODIN v10.68's CATALYSTS_DATA:

1. RGNX — RGX-121 (CRL Feb 7) ✅ In DB
2. IRON — Bitopertin (CRL Feb 13) ✅ In DB
3. ASND — TransCon CNP (pending Feb 28) ✅ In DB
4. CAPR — Deramiocel (CRL Jul 11 / data Dec 3) ✅ In DB (but scored for BLA, not data readout)
5. NVO — Oral Semaglutide (Approved Dec 22) ✅ In DB
6. AZN — Tezspire CRSwNP (Approved Oct 17) — need to verify

### EVENTS NOT IN ODIN'S DATABASE (Blind Spots)

All other events (approximately 30) were NOT scored by ODIN. These represent either:
- Events that were in the DB but removed after resolution
- Events ODIN never covered (true blind spots)

---

## ODIN VERIFIED WINS CROSS-REFERENCE

| Ticker | Verified Wins File | Actual Event Type | Date | Notes |
|--------|-------------------|-------------------|------|-------|
| CAPR | WIN +404% at 75% | DATA READOUT (not PDUFA) | Dec 3, 2025 | BLA got CRL Jul 11; stock rallied on HOPE-3 data |
| MIST | WIN +130% at 72% | APPROVAL (post-CRL resub) | Dec 12, 2025 | Original CRL Mar 28, 2025 for CMC |
| TOVX | WIN +92% at 72% | DATA READOUT | ~Nov 2025 | Not a PDUFA event |
| ARWR | WIN +52% at 91% | APPROVAL | Nov 18, 2025 | Clean approval |
| SNDX | WIN +51% at 85% | APPROVAL | Nov 6, 2025 | sNDA expansion |
| KURA | WIN +45% at 88% | APPROVAL | Nov 13, 2025 | Approved ahead of PDUFA |
| ARCT/ARQT | WIN +27% at 90% | APPROVAL | Oct 6, 2025 | Zoryve AD expansion |
| CYTK | WIN +25% at 92% | APPROVAL | Dec 19, 2025 | Clean approval |
| AMRX | WIN +24% at 85% | APPROVAL | Dec 22, 2025 | Biosimilar |
| AGIO | WIN +23% at 82% | APPROVAL | Dec 23, 2025 | sNDA thalassemia |
| NVO | WIN +13% at 95% | APPROVAL | Dec 22, 2025 | Mega-cap, first oral GLP-1 |
| AZN | WIN +8% at 92% | APPROVAL | Oct 17, 2025 | sNDA nasal polyps, large-cap |
| BHVN | AVOID at 38% | CRL | Nov 4, 2025 | External control issues |
| RGNX | AVOID at 45% | CRL | Feb 7, 2026 | Surrogate, clinical hold |
| ASND | AVOID at 58% | DELAY | Nov 25, 2025 | 3-month extension |
